Showing results (101-110 of 143) with videos related to
Sort By:
Pageof 15
The Oncologist|May 18, 2024
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLCAllison E B Chang, Andrew J Piper-Vallillo, Raymond H Mak, et al.Lung Cancer (Amsterdam, Netherlands)|September 16, 2025
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancerFangdi Sun, Mandeep K Banwait, Surbhi Singhal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 InsertionsZofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief ReportXiuning Le, Christina Baik, Byoung Chul Cho, et al.European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARDZofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.American Journal of Hematology|February 22, 2019
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitorsRebecca Karp Leaf, Christopher Ferreri, Deepa Rangachari, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET InhibitorIbiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, et al.JTO Clinical and Research Reports|March 7, 2023
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.JTO Clinical and Research Reports|May 31, 2022
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional ExperienceA J Piper-Vallillo, Julia K Rotow, Jacqueline V Aredo, et al.JTO Clinical and Research Reports|September 21, 2023
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional StudyLeou Ismael Banla, Alice Tzeng, John P Baillieul, et al.Pageof 15